VBI Vaccines (VBIV) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

VBIV Stock Forecast


VBI Vaccines stock forecast is as follows: a rating consensus of 'Strong Buy', based on 2 wall street analysts offering a 1-year stock forecast.

VBIV Analyst Ratings


Strong Buy

According to 2 Wall Street analysts, VBI Vaccines's rating consensus is 'Strong Buy'. The analyst rating breakdown for VBIV stock is 1 'Strong Buy' (50.00%), 0 'Buy' (0.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 09, 2022Raymond JamesStrong BuyStrong BuyHold
Apr 26, 2022Zacks Investment Research-HoldUpgrade
Row per page
Go to

VBI Vaccines's last stock rating was published by Raymond James on Aug 09, 2022. The company gave VBIV a "Strong Buy" rating, the same as its previous rate.

VBI Vaccines Financial Forecast


VBI Vaccines Revenue Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17
Revenue-----------$485.00K$293.00K--$126.00K$81.00K--$301.00K$164.00K--$415.00K$574.00K--$360.00K$178.00K$127.00K
Avg Forecast$10.48M$9.29M$7.80M$6.55M$4.56M$3.88M$3.19M$2.85M$5.36M$13.25M$929.00K$817.00K$1.98M$1.29M$704.33K$120.00K$137.33K$203.67K$481.33K$485.00K$407.00K$328.25K$631.25K$655.25K$729.75K$702.67K$489.00K$443.33K$161.05K$112.27K
High Forecast$10.48M$9.29M$7.80M$6.55M$4.56M$3.88M$3.19M$2.85M$5.36M$13.25M$929.00K$817.00K$1.98M$1.29M$704.33K$120.00K$137.33K$203.67K$481.33K$485.00K$407.00K$328.25K$631.25K$655.25K$729.75K$702.67K$489.00K$443.33K$193.26K$134.73K
Low Forecast$10.48M$9.29M$7.80M$6.55M$4.56M$3.88M$3.19M$2.85M$5.36M$13.25M$929.00K$817.00K$1.98M$1.29M$704.33K$120.00K$137.33K$203.67K$481.33K$485.00K$407.00K$328.25K$631.25K$655.25K$729.75K$702.67K$489.00K$443.33K$128.84K$89.82K
# Analysts111111111111111111115510744851115
Surprise %-----------0.59%0.15%--1.05%0.59%--0.62%0.40%--0.63%0.79%--0.81%1.11%1.13%

VBI Vaccines's average Quarter revenue forecast for Jul 23 based on 1 analysts is $929.00K, with a low forecast of $929.00K, and a high forecast of $929.00K. VBIV's average Quarter revenue forecast represents a 91.55% increase compared to the company's last Quarter revenue of $485.00K (Mar 23).

VBI Vaccines EBITDA Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17
# Analysts111111111111111111115510744851115
EBITDA-----------$-18.50M$-20.27M--$-15.37M$-20.34M--$-15.06M$-13.59M--$-8.88M$-3.25M--$-13.40M$-11.47M$-8.68M
Avg Forecast$-10.48M$-9.29M$-7.80M$-6.55M$-4.56M$-3.88M$-3.19M$-17.76M$-5.36M$-13.25M$-929.00K$-18.99M$-9.89M$-1.29M$-704.33K$-20.31M$-137.33K$-203.67K$-481.33K$-12.67M$-407.00K$-328.25K$-631.25K$-8.44M$-729.75K$-702.67K$-489.00K$-13.71M$-10.20M$-6.90M
High Forecast$-10.48M$-9.29M$-7.80M$-6.55M$-4.56M$-3.88M$-3.19M$-14.21M$-5.36M$-13.25M$-929.00K$-15.19M$-7.91M$-1.29M$-704.33K$-16.25M$-137.33K$-203.67K$-481.33K$-10.13M$-407.00K$-328.25K$-631.25K$-6.76M$-729.75K$-702.67K$-489.00K$-10.97M$-8.16M$-5.52M
Low Forecast$-10.48M$-9.29M$-7.80M$-6.55M$-4.56M$-3.88M$-3.19M$-21.31M$-5.36M$-13.25M$-929.00K$-22.79M$-11.87M$-1.29M$-704.33K$-24.38M$-137.33K$-203.67K$-481.33K$-15.20M$-407.00K$-328.25K$-631.25K$-10.13M$-729.75K$-702.67K$-489.00K$-16.45M$-12.24M$-8.28M
Surprise %-----------0.97%2.05%--0.76%148.07%--1.19%33.39%--1.05%4.46%--0.98%1.12%1.26%

undefined analysts predict VBIV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than VBI Vaccines's previous annual EBITDA (undefined) of $NaN.

VBI Vaccines Net Income Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17
# Analysts111111111111111111115510744851115
Net Income-----------$-37.42M$-19.64M--$-25.65M$-15.64M--$-17.79M$-15.81M--$-8.36M$-10.88M--$-14.91M$-12.34M$-8.64M
Avg Forecast$-737.54K$-1.23M$-2.21M$-2.95M$-3.69M$-5.41M$-7.87M$-18.58M$-5.41M$-3.44M$-53.10M$-19.87M$-10.42M$-59.00M$-51.63M$-21.25M$-54.09M$-51.63M$-49.17M$-14.71M$-42.78M$-33.19M$-29.50M$-9.75M$-42.41M$-90.96M$-103.26M$-14.61M$-10.81M$-7.27M
High Forecast$-737.54K$-1.23M$-2.21M$-2.95M$-3.69M$-5.41M$-7.87M$-14.86M$-5.41M$-3.44M$-53.10M$-15.90M$-8.34M$-59.00M$-51.63M$-17.00M$-54.09M$-51.63M$-49.17M$-11.76M$-42.78M$-33.19M$-29.50M$-7.80M$-42.41M$-90.96M$-103.26M$-11.68M$-8.65M$-5.82M
Low Forecast$-737.54K$-1.23M$-2.21M$-2.95M$-3.69M$-5.41M$-7.87M$-22.30M$-5.41M$-3.44M$-53.10M$-23.85M$-12.50M$-59.00M$-51.63M$-25.50M$-54.09M$-51.63M$-49.17M$-17.65M$-42.78M$-33.19M$-29.50M$-11.70M$-42.41M$-90.96M$-103.26M$-17.53M$-12.97M$-8.73M
Surprise %-----------1.88%1.88%--1.21%0.29%--1.21%0.37%--0.86%0.26%--1.02%1.14%1.19%

VBI Vaccines's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VBIV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

VBI Vaccines SG&A Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17
# Analysts111111111111111111115510744851115
SG&A-----------$13.28M$15.89M--$10.93M$12.53M--$6.75M$7.13M--$4.06M$-2.48M--$3.96M$3.42M$3.04M
Avg Forecast$299.87M$265.76M$223.25M$187.37M$130.58M$110.92M$91.24M$81.60M$153.35M$379.12M$26.58M$23.37M$56.63M$36.99M$20.15M$3.43M$3.93M$5.83M$13.77M$13.88M$11.64M$9.39M$18.06M$18.75M$20.88M$20.10M$13.99M$12.68M$4.61M$3.21M
High Forecast$299.87M$265.76M$223.25M$187.37M$130.58M$110.92M$91.24M$81.60M$153.35M$379.12M$26.58M$23.37M$56.63M$36.99M$20.15M$3.43M$3.93M$5.83M$13.77M$13.88M$11.64M$9.39M$18.06M$18.75M$20.88M$20.10M$13.99M$12.68M$5.53M$3.85M
Low Forecast$299.87M$265.76M$223.25M$187.37M$130.58M$110.92M$91.24M$81.60M$153.35M$379.12M$26.58M$23.37M$56.63M$36.99M$20.15M$3.43M$3.93M$5.83M$13.77M$13.88M$11.64M$9.39M$18.06M$18.75M$20.88M$20.10M$13.99M$12.68M$3.69M$2.57M
Surprise %-----------0.57%0.28%--3.18%3.19%--0.49%0.61%--0.22%-0.12%--0.31%0.74%0.95%

VBI Vaccines's average Quarter SG&A projection for Jul 23 is $26.58M, based on 1 Wall Street analysts, with a range of $26.58M to $26.58M. The forecast indicates a 100.08% rise compared to VBIV last annual SG&A of $13.28M (Mar 23).

VBI Vaccines EPS Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17
# Analysts111111111111111111115510744851115
EPS-----------$-4.34$-0.08--$-2.98$-0.06--$-0.07$-0.06--$-1.50$-0.10--$-0.15$-0.19$-0.22
Avg Forecast$-0.03$-0.05$-0.09$-0.12$-0.15$-0.22$-0.32$-0.53$-0.22$-0.14$-2.16$-2.27$-2.10$-2.40$-2.10$-2.40$-2.20$-2.10$-2.00$-1.80$-1.74$-1.35$-1.20$-1.88$-1.73$-3.70$-4.20$-4.60$-0.15$-0.16
High Forecast$-0.03$-0.05$-0.09$-0.12$-0.15$-0.22$-0.32$-0.53$-0.22$-0.14$-2.16$-2.27$-2.10$-2.40$-2.10$-2.40$-2.20$-2.10$-2.00$-1.80$-1.74$-1.35$-1.20$-1.88$-1.73$-3.70$-4.20$-4.60$-0.12$-0.13
Low Forecast$-0.03$-0.05$-0.09$-0.12$-0.15$-0.22$-0.32$-0.53$-0.22$-0.14$-2.16$-2.27$-2.10$-2.40$-2.10$-2.40$-2.20$-2.10$-2.00$-1.80$-1.74$-1.35$-1.20$-1.88$-1.73$-3.70$-4.20$-4.60$-0.18$-0.19
Surprise %-----------1.92%0.04%--1.24%0.03%--0.04%0.04%--0.80%0.06%--0.03%1.27%1.38%

According to undefined Wall Street analysts, VBI Vaccines's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VBIV previous annual EPS of $NaN (undefined).

VBI Vaccines Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
GRTSGritstone bio$0.03$4.6715466.67%Buy
VBIVVBI Vaccines$0.07$5.007042.86%Strong Buy
ALLOAllogene Therapeutics$3.00$29.00866.67%Buy
ONTXTraws Pharma$1.00$7.00600.00%Buy
OCGNOcugen$0.96$5.00420.83%Buy
GOVXGeoVax Labs$1.79$8.00346.93%Buy
ANVSAnnovis Bio$8.73$25.67194.04%Buy
VXRTVaxart$0.73$2.00173.97%Hold
ANIXAnixa Biosciences$3.45$7.50117.39%Buy
BBIOBridgeBio Pharma$25.20$45.0078.57%Buy
AUPHAurinia Pharmaceuticals$7.21$10.7549.10%Buy
ARDXArdelyx$5.89$8.7548.56%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy

VBIV Forecast FAQ


Yes, according to 2 Wall Street analysts, VBI Vaccines (VBIV) is considered a 'Strong Buy'. The rating consensus is based on 1 'Strong Buy' and 0 'Buy' recommendations, accounting for 50.00% of VBIV's total ratings.

VBI Vaccines's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $14.48M (high $14.48M, low $14.48M), average EBITDA is $-29.389M (high $-25.837M, low $-32.94M), average net income is $-35.544M (high $-31.828M, low $-39.26M), average SG&A $414.34M (high $414.34M, low $414.34M), and average EPS is $-1.22 (high $-1.22, low $-1.22). VBIV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.12M (high $34.12M, low $34.12M), average EBITDA is $-34.122M (high $-34.122M, low $-34.122M), average net income is $-7.13M (high $-7.13M, low $-7.13M), average SG&A $976.25M (high $976.25M, low $976.25M), and average EPS is $-0.29 (high $-0.29, low $-0.29).

Based on VBI Vaccines's last annual report (Dec 2022), the company's revenue was $1.08M, which missed the average analysts forecast of $4.1M by -73.59%. Apple's EBITDA was $-81.82M, beating the average prediction of $-32.201M by 154.09%. The company's net income was $-141M, missing the average estimation of $-142M by -0.95%. Apple's SG&A was $56.12M, missing the average forecast of $117.21M by -52.12%. Lastly, the company's EPS was $-0.55, missing the average prediction of $-9 by -93.89%. In terms of the last quarterly report (Mar 2023), VBI Vaccines's revenue was $485K, missing the average analysts' forecast of $817K by -40.64%. The company's EBITDA was $-18.499M, missing the average prediction of $-18.993M by -2.60%. VBI Vaccines's net income was $-37.422M, beating the average estimation of $-19.872M by 88.31%. The company's SG&A was $13.28M, missing the average forecast of $23.37M by -43.17%. Lastly, the company's EPS was $-4.34, beating the average prediction of $-2.265 by 91.61%